ClinicalTrials.gg
RecruitingNCT05173597Updated Mar 30, 2025

Real-world Evidence on Follitropin Delta Individual Dosing

An observational study in Infertility and Sterility, sponsored by University of Luebeck. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by University of Luebeck · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
850
Ages
18 Years to 44 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Infertility with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Infertility · Germany.

Planned enrollment
6th of 10
850 · median 1,023
Started
2021
with 1 other
Observational
10 of 28
4 open now
Registered
25th of 28
by date
Lead sponsor
4 of 28
University of Luebeck

Among the 28 studies in Infertility with a site in Germany, this one is the 6th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2021, is one of 10 observational ones, and was the 25th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

4 of the 28 studies in Infertility with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 44 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Infertility with a site in Germany, or all of them as a file.
02

Study summary

As part of the in vitro fertilisation treatment, ovarian stimulation is routinely performed. For this purpose, FSH preparations are used. Follitropin delta is a FSH preparation that is approved for a wide range of applications and is dosed individually according to body weight and serum anti-Müllerian hormone (AMH). Body weight is used to estimate the distribution volume of the glycoprotein FD in the patient and is thus a proxy of exposure. The AMH is used to estimate the ovarian reserve and thus the number of follicles in the ovaries that can be recruited by Follitropin delta stimulation. An algorithm is used for individual dosing. The aim of individual dosing is to reduce the probability of an under or overreaction of the ovaries to FSH therapy.

In contrast to phase III registration studies, patients with severe overweight and underweight, as well as very high and very low AMH values and associated disorders of the menstrual cycle and oocyte maturation, are also found in the reality of care. The performance of the dosing algorithm and thus the results of ovarian stimulation in these subgroups of patients have so far been insufficiently investigated in the phase III registration trials.

In the present study no statistical hypothesis will be tested. The study is descriptive by design and the analyses are descriptive and exploratory. NIS is chosen in order to explore how the individualized dosing regimen of REKOVELLE® performs in routine clinical practice and to investigate the effectiveness and safety of REKOVELLE® under real-world conditions. This is a monocentric, prospective, non-interventional cohort study conducted in normal care setting in a fertility clinic that will collect information from 850 women undergoing up to two cycles of IVF or ICSI treatment with controlled ovarian stimulation with REKOVELLE®.

Read the detailed description

Infertility is often defined as the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. Many factors (age, gynaecological problems, life style factors) can cause infertility and may involve the male, the female or both.

Global estimates suggest that the 12-month prevalence rate of infertility ranged from 3.5% to 16.7% in developed countries, with a median prevalence of 9% worldwide for women aged 20 - 44 years. A recent study estimated that 1.9% of child-seeking women aged 20 - 44 years experienced primary infertility (unable to have a live birth) and 10.5% secondary infertility (at least one live birth). The proportion of infertile couples seeking any infertility medical care ranges from 51% in less developed countries to 56% in developed countries, and 22% actually received infertility treatment.

Among fertility treatment, controlled ovarian stimulation (COS) with recombinant or urinary follicle stimulating hormone (FSH) and human menotropin gonadotropin (hMG) aims to obtain an adequate number of competent oocytes to be used for assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI), with minimum risks for the woman.

The ovarian response is influenced by the dose of gonadotropin, but there is a large variability across patients for the same dose of gonadotropin. A standard starting dose of gonadotropin in women with a low ovarian reserve may result in a poor ovarian response. In women with a high ovarian reserve, the same dose may result in an excessive response and therefore increases the risk of complications such as the ovarian hyperstimulation syndrome (OHSS). OHSS is a rare but critical complication associated with gonadotropin use. Severe OHSS occurs in approximately 1.4 % of all COS cycles.

Individualizing COS regimens is therefore crucial to ensure an appropriate dosing from the start of stimulation in order to reduce the risk of cycle cancellation due to poor response and minimize the iatrogenic risks due to an excessive response.The use of biomarkers, which can predict ovarian response to exogenous FSH stimulation, has been extensively investigated. Among the different biomarkers, the serum level of anti-müllerian hormone (AMH) is currently considered as the most robust marker of the ovarian reserve. In addition, AMH serum levels shows relative stability and consistency during the menstrual cycle, and can therefore be measured at any time of the menstrual cycle.

In December 2016, Ferring received Marketing Authorisation approval from the European Commission for follitropin delta (FE 999049) under the trade name REKOVELLE®, a new human recombinant FSH (rFSH). The indication is: "Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle." This is the first rFSH treatment to be administered with an individualised dosing regimen, based on a woman's serum AMH level as well as her body weight.

This individualised dosing regimen was established in a phase-2 AMH-stratified trial conducted in 265 IVF/ICSI patients using pharmacokinetic (PK) and pharmacodynamic (PD) modelling and simulation. A robust assay was developed in collaboration with Roche Diagnostics to ensure a reliable assessment of AMH levels at the standards intended for companion diagnostics.

The efficacy and safety of Follitropin Delta was first evaluated in the ESTHER-1 (Evidence- based Stimulation Trial with Human rFSH in Europe and Rest of World) phase-3 trial, which compared the individualized Follitropin Delta dosing based on AMH level and body weight with conventional Follitropin Alfa (Gonal-F®) dosing. Patients who did not achieve an ongoing pregnancy could continue in the ESTHER-2 phase-3 trial, which evaluated the immunogenicity in repeated COS cycles. The results of the phase-3 trials showed that individualized Follitropin Delta was non-inferior to conventional Follitropin Alfa for ongoing pregnancy and ongoing implantationrates. Overall, women treated with individualized Follitropin Delta dosing reached more frequently the prespecified optimum oocyte yield (8-14 oocytes), with fewer cases of extreme ovarian responses, and a reduced need for OHSS preventive measures.

The phase III clinical program has demonstrated that REKOVELLE® is an effective and well-tolerated treatment for controlled ovarian stimulation. Nevertheless, while clinical trials provide crucial information about drug efficacy and safety under controlled conditions in a selected group of patients, broader information is needed to explore how the individualized dosing regimen of REKOVELLE® is used in routine clinical practice and to investigate the effectiveness and safety of REKOVELLE® under real-world conditions.

03

Conditions studied

  • Infertility
  • Sterility

Keywords

  • In-Vitro-Fertilisation
  • Assisted reproduction
  • Ovarian Stimulation
  • Ovarian Hyperstimulation Syndrome
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The included patients are adult women from the routine clinical care settings with indication for ovarian stimulation with follitropin delta in a GnRH-antagonist protocol who are making a first treatment attempt IVF or ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 to ≤ 44 years at enrolment

    • Planned stimulation in a fixed or flexible GnRH antagonist protocol
    • Planned use of follitropin delta for ovarian stimulation as per SmPC
    • Planned IVF or ICSI treatment with ejaculated or cryopreserved male germ cells, autologous or heterologous, with or without planned genetic testing of the oocytes or embryos
    • Planned preservation of MII oocytes (fertility preservation)
    • Planned triggering of final oocyte maturation with hCG or a GnRH agonist
    • Willingness and consent to participate

Exclusion criteria

Exclusion Criteria:

  • Serum AMH within 12 months prior to treatment ≤0.3 ng/ml
  • Most recent serum AMH value before start of stimulation older than 12 months
  • Serum AMH value not determined in Roche Elecsys immunoassays
  • Pre-treatment with a combined oral "pill" consisting of ethinyl estradiol and a synthetic progestogen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
850 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients receiving treatment with Follitropin-delta

    The included patients are adult women from the routine clinical care settings with indication for ovarian stimulation with follitropin delta in a GnRH-antagonist protocol who are making a first treatment attempt IVF or ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.

    Drug: Follitropin delta

Interventions

  • REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.

    Also known as: REKOVELLE® (follitropin delta)

06

What researchers measure

Primary outcomes

  1. Ovarian response

    Number of cumulus-oocyte-complexes of the individual dosing regimen of follitropin delta for controlled ovarian stimulation for in-vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) in a cohort of patients from a real-world setting with focus on high body weight.

    Time frame: 2021-2022

Secondary outcomes

  1. Overall treatment outcome

    Incidence of live birth stratified for low, normal and high AMH and body weight

    Time frame: 2021-2022

  2. Change in body weight

    Determine change in body weight between 1st and 2nd cycle in subjects undergoing two cycles

    Time frame: 2021-2022

  3. Incidence of dose changes

    Incidence of dose changes between 1st and 2nd treatment cycle in subjects undergoing two cycles

    Time frame: 2021-2022

  4. Intra-individual variation of ovarian response

    Intra-individual variation of the number of cumulus-oocyte-complexes retrieved between 1st and 2nd treatment cycle in subjects undergoing two cycles, stratified for low, normal and high AMH and body weight and cycle regularity

    Time frame: 2021-2022

  5. Measurement of correlation of variance of body weight and AMH

    Correlation coefficient of variance of body weight and AMH with variance of ovarian response between 1st and 2nd cycle in subjects undergoing two cycles

    Time frame: 2021-2022

  6. Comparison of intra-individual variance

    Intra-individual variance in the number of cumulus-oocyte-complexes retrieved between first and second cycle in subgroups on the prospectively collected data and historical controls

    Time frame: 2021-2022

  7. Safety of treatment

    Incidence of adverse events related to treatment and assessed by CTCAE v4.0 of follitropin delta in a real-world setting

    Time frame: 2021-2022

  8. Change in AMH

    Difference in serum AMH values between 1st and 2nd cycle in subjects undergoing two cycles

    Time frame: 2021-2022

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, Vanderpoel S; International Committee for Monitoring Assisted Reproductive Technology; World Health Organization. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril. 2009 Nov;92(5):1520-4. doi: 10.1016/j.fertnstert.2009.09.009. Epub 2009 Oct 14. PubMed 19828144 ↗
  • Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile male: a committee opinion. Fertil Steril. 2015 Mar;103(3):e18-25. doi: 10.1016/j.fertnstert.2014.12.103. Epub 2015 Jan 15. PubMed 25597249 ↗
  • Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2012 Aug;98(2):302-7. doi: 10.1016/j.fertnstert.2012.05.032. Epub 2012 Jun 13. PubMed 22698637 ↗
  • Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007 Jun;22(6):1506-12. doi: 10.1093/humrep/dem046. Epub 2007 Mar 21. PubMed 17376819 ↗
  • Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356. doi: 10.1371/journal.pmed.1001356. Epub 2012 Dec 18. PubMed 23271957 ↗
  • Arce JC, Andersen AN, Fernandez-Sanchez M, Visnova H, Bosch E, Garcia-Velasco JA, Barri P, de Sutter P, Klein BM, Fauser BC. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014 Dec;102(6):1633-40.e5. doi: 10.1016/j.fertnstert.2014.08.013. Epub 2014 Sep 23. PubMed 25256937 ↗
  • Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008 Nov;90(5 Suppl):S188-93. doi: 10.1016/j.fertnstert.2008.08.034. PubMed 19007627 ↗
  • Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D'Hooghe T, Castilla JA, Calhaz-Jorge C, De Geyter C, Goossens V; European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHREdagger. Hum Reprod. 2014 Oct 10;29(10):2099-113. doi: 10.1093/humrep/deu175. Epub 2014 Jul 27. PubMed 25069504 ↗
  • Klemetti R, Sevon T, Gissler M, Hemminki E. Complications of IVF and ovulation induction. Hum Reprod. 2005 Dec;20(12):3293-300. doi: 10.1093/humrep/dei253. Epub 2005 Aug 26. PubMed 16126753 ↗
  • La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 Jan-Feb;20(1):124-40. doi: 10.1093/humupd/dmt037. Epub 2013 Sep 29. PubMed 24077980 ↗
  • Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006 Nov-Dec;12(6):685-718. doi: 10.1093/humupd/dml034. Epub 2006 Aug 4. PubMed 16891297 ↗
  • Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013 Mar 15;99(4):963-9. doi: 10.1016/j.fertnstert.2012.11.051. Epub 2013 Jan 8. PubMed 23312225 ↗
  • La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 Mar-Apr;16(2):113-30. doi: 10.1093/humupd/dmp036. Epub 2009 Sep 30. PubMed 19793843 ↗
  • Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod. 2012 Jun;27(6):1829-39. doi: 10.1093/humrep/des101. Epub 2012 Apr 3. PubMed 22473395 ↗
  • Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014 Sep-Oct;20(5):688-701. doi: 10.1093/humupd/dmu020. Epub 2014 May 12. PubMed 24821925 ↗
  • La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006 Dec;21(12):3103-7. doi: 10.1093/humrep/del291. Epub 2006 Aug 21. PubMed 16923748 ↗
  • Gassner D, Jung R. First fully automated immunoassay for anti-Mullerian hormone. Clin Chem Lab Med. 2014 Aug;52(8):1143-52. doi: 10.1515/cclm-2014-0022. PubMed 24622790 ↗
  • Nyboe Andersen A, Nelson SM, Fauser BC, Garcia-Velasco JA, Klein BM, Arce JC; ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017 Feb;107(2):387-396.e4. doi: 10.1016/j.fertnstert.2016.10.033. Epub 2016 Nov 29. PubMed 27912901 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2026, 51 months after the start.

Of 209 non-industry observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 100. This study's planned 51 months is above that.

Counting every sponsor, half of 240 studies reached it within 39 months; a quarter within 16 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Dec 30, 2021
StartActual
Dec 8, 2021
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05173597
Lead sponsor
University of Luebeck
Responsible party
Prof. Dr. med. M.Sc. Georg Griesinger (Professor, University of Luebeck) — Principal investigator
First posted
Dec 30, 2021
Start date
Dec 8, 2021
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Mar 30, 2025

Study contacts

Georg Griesinger, MD
Contact
georg.griesinger@uni-luebeck.de
+49 451-500-41950
Tanja Eggersmann, MD
Contact
TanjaKristina.Eggersmann@uksh.de
+49 451-500-41950

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion